Genome Therapeutics And ICAgen Collaborate To Conduct Drug Target Analysis

Genome Therapeutics Corp. and ICAgen, Inc. have announced an agreement that utilizes Genome Therapeutics’ technology to facilitate the assessment and development of a clinical trial design protocol for one of ICAgen’s ion channel targets. The genomics technology utilizes polymorphism analysis in subgroups of the target patient population to rapidly determine the target’s efficacy and thus Read more about Genome Therapeutics And ICAgen Collaborate To Conduct Drug Target Analysis[…]

CytoGenix Licenses Trovec Antisense Delivery System To PharmaGenix

CytoGenix Inc. has executed the first license for the use of its proprietary single stranded DNA intracellular expression vector (TroVec) to PharmaGenix LLC., owned jointly by CYGX and PCCA (Professional Compounding Centers of America Inc). PharmaGenix is the first company to combine the traditional science and skills of compounding pharmacists with those molecular biologists and Read more about CytoGenix Licenses Trovec Antisense Delivery System To PharmaGenix[…]

Roche And deCODE Genetics Identify Schizophrenia Gene

Roche and deCODE genetics have announced that scientists at deCODE together with psychiatrists from the Icelandic healthcare system have identified a gene linked to schizophrenia. This discovery is the result of a genome-wide screen conducted with the participation of 400 Icelandic schizophrenia patients and an equal number of their unaffected family members. The study marks Read more about Roche And deCODE Genetics Identify Schizophrenia Gene[…]

Lexicon Genetics Grants Bristol-Myers Squibb Sublicense

Lexicon Genetics Incorporated has granted a non-exclusive sublicense to Bristol- Myers Squibb Company for the use of certain aspects of Lexicon’s positive-negative selection and isogenic DNA technologies. Bristol-Myers Squibb will use the technology for the generation of knockout mice for internal research purposes to gain predictive information about gene products that are valid drug targets Read more about Lexicon Genetics Grants Bristol-Myers Squibb Sublicense[…]

ArQule And Genome Therapeutics Sign Anti-infective Agreement

ArQule, Inc. and Genome Therapeutics have announced a new drug discovery collaboration uniting their key strengths in the genomics and chemistry fields. ArQule will use their new Parallel Track Drug Discovery program to screen and optimise compounds against an expanded number of proprietary validated anti-infective targets which Genome Therapeutics has derived from its PathoGenome Database. Read more about ArQule And Genome Therapeutics Sign Anti-infective Agreement[…]

Medarex And Oxford GlycoSciences Form Alliance

Oxford GlycoSciences Plc and Medarex, Inc. have announced an alliance to develop novel therapeutics produced through the joint application of Medarex’s fully human monoclonal antibody technology and OGS’s proprietary proteomics technology for high-throughput protein analysis and target validation. Antibodies are increasingly being recognized as a rapid and efficient way to move potential products from the Read more about Medarex And Oxford GlycoSciences Form Alliance[…]

Invitrogen Commercializes Novel Thermostable Enzyme

Invitrogen Corporation and Diversa Corporation have announced the launch of ThermalAce DNA Polymerase, a novel enzyme that improves the performance of DNA amplification for the widely used polymerase chain reaction (PCR). The enzyme is an extremely stable DNA polymerase that improves the yield of DNA amplifications while doing so with a high degree of accuracy. Read more about Invitrogen Commercializes Novel Thermostable Enzyme[…]

Variagenics Gains Patent For MTHFR Gene

The United States Patent and Trademark Office has issued U.S. Patent No. 6,074,821 entitled “cDNA for Human Methylenetetrahydrofolate Reductase.” to VARIAGENICS, INC. Assigned to McGill University in Montreal, Canada, the patent has been exclusively licensed to VARIAGENICS under the terms of a March 25, agreement. In connection with the licensing arrangement, VARIAGENICS is supporting research Read more about Variagenics Gains Patent For MTHFR Gene[…]

Genzyme, AGTC Announce Gene Therapy Collaboration

Genzyme Corporation and Applied Genetic Technologies (AGTC), a private development-stage biotechnology company, announced today that they have entered into a research collaboration to jointly develop novel therapeutics involving gene therapy.Through the collaboration, Genzyme gains access to AGTC’s extensive expertise using Adeno-Associated Virus (AAV) vectors to deliver genes to patients, including access to AGTC’s novel high-yield Read more about Genzyme, AGTC Announce Gene Therapy Collaboration[…]

Exelixis And Bristol-Myers Squibb Extend Oncology Collaboration

Exelixis, Inc. has extended and expanded its oncology research collaboration with Bristol-Myers Squibb Company under which the two companies will continue to identify and validate molecular targets implicated in cancer. The original agreement was established for a three-year term in July 2001. Subject to the terms of their amended agreement, Exelixis and Bristol-Myers Squibb have Read more about Exelixis And Bristol-Myers Squibb Extend Oncology Collaboration[…]